Wegovy® (semaglutide) is an FDA approved prescription medication indicated for chronic weight management in adults with obesity and in adults who are overweight with at least one weight related comorbidity. It promotes weight loss by activating GLP-1 receptors, which enhance satiety, reduce appetite, and decrease overall caloric intake.
During your clinical consultation at Altius, we take the time to understand your health history, weight management goals, and lifestyle. Our licensed medical providers will assess whether Wegovy® is an appropriate option for you, explain how it works, and review the expected benefits and potential risks. If prescribed, treatment typically starts at a low dose to minimize side effects, with gradual dose increases over several weeks as tolerated.
Wegovy® is administered as a once weekly subcutaneous injection using a small, simple needle, typically in the abdomen or thigh. Our team will provide clear instruction to ensure you feel confident administering the medication. All treatments at Altius require a consultation with a licensed healthcare provider, and prescriptions are issued solely at the provider’s clinical discretion following a comprehensive review of your medical history and overall health profile.
Common side effects of Wegovy® may include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, dizziness, bloating, belching, gas, heartburn, symptoms similar to stomach flu, and upper respiratory symptoms such as runny nose or sore throat. Low blood sugar may occur, particularly in individuals with type 2 diabetes who are using insulin or insulin secretagogues.
Serious adverse effects may include the potential risk of thyroid tumors, including thyroid cancer. Wegovy® should not be used in individuals with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2. This is not a complete list of possible side effects. Patients should contact their healthcare provider if they experience side effects that are persistent, severe, or concerning.
For further safety information, please visit https://www.novo-pi.com/wegovy.pdf.
**The information provided on this website is for informational purposes only and is not intended to replace professional medical advice. Always consult a qualified healthcare provider regarding any questions about your health, diagnosis, or treatment.
**Medication and FDA Information: Our clinic prescribes medications based on your individual health profile and clinical appropriateness. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA approved for chronic weight management. Other medications, including Ozempic® (semaglutide) and Mounjaro® (tirzepatide), are FDA approved for the treatment of type 2 diabetes and may be prescribed off label for weight loss at the provider’s clinical discretion.
**Compounded Medications: Our clinic may also offer compounded medications, such as Sermorelin or compounded GLP-1 therapies, prepared by a state licensed sterile compounding pharmacy. Compounded medications are not FDA approved, and the FDA does not review or verify their safety, efficacy, or manufacturing quality.
**Trademarks and Affiliation: Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Altius Performance Medicine is not affiliated with, endorsed by, or an official partner of Novo Nordisk A S or Eli Lilly and Company.
**FSA and HSA eligibility and coverage vary by plan and administrator.
Testimonials
- Dillon C.
Meet Our Providers
